Durvalumab plus tremelimumab for advanced hepatocellular carcinoma is associated with a neutrophil/lymphocyte ratio

被引：0
|
作者：
Sugimoto, Rie [1 ]
Senjyuu, Takeshi [2 ]
Aratake, Yoshifusa [3 ]
Kuwano, Akifumi [4 ]
Ueda, Akihiro [5 ]
Nakamura, Tsukasa [6 ]
Goya, Takeshi [7 ]
Morita, Yuusuke [1 ]
Tanaka, Yuki [1 ]
Kojima, Motoyuki [3 ]
Tanaka, Masatake [7 ]
机构：
[1] NHO Kyushu Canc Ctr, Dept Hepatobiliary Pancreatol, Fukuoka, Japan
[2] Kyushu Rosai Hosp, Kitakyushu, Fukuoka, Japan
[3] NHO Kyusyu Med Ctr, Fukuoka, Japan
[4] Iizuka Hosp, Iizuka, Fukuoka, Japan
[5] Saiseikai Fukuoka Gen Hosp, Fukuoka, Japan
[6] Fukuoka City Hosp, Fukuoka, Japan
[7] Kyushu Univ, Dept Med & Bioregulatory Sience, Fukuoka, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2184
引用
收藏
页码：963 / 963
页数：1
相关论文
共 50 条
  • [21] Durvalumab and tremelimumab for hepatocellular carcinoma in patients listed for a liver transplant
    Sohal, Davendra
    Abouelezz, Khaled Fahmy
    Moreland, Katie
    Quillin, Ralph
    Lemon, Kristina
    Rojan, Adam
    Olowokure, Olugbenga Olanrele
    Kord, Ali
    Shah, Shimul
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Plasma growth hormone as a prognostic biomarker to durvalumab and tremelimumab in patients with advanced hepatocellular carcinoma.
    Chamseddine, Shadi
    LaPelusa, Michael Brian
    Xiao, Lianchun
    Abugabal, Yehia I.
    Lee, Sunyoung S.
    Hu, Zishuo Ian
    Hu, Zishuo Ian
    Hatia, Rikita
    Hassan, Manal
    Yao, James C.
    Duda, Dan G.
    Datar, Saumil
    Amin, Hesham M.
    Kaseb, Ahmed Omar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [23] Phase Ib trial of durvalumab plus tremelimumab in combination with particle radiotherapy in advanced hepatocellular carcinoma patients with macrovascular invasion: DEPARTURE trial
    Ogasawara, Sadahisa
    Koroki, Keisuke
    Makishima, Hirokazu
    Wakatsuki, Masaru
    Sakuma, Takafumi
    Fujita, Naoto
    Kanzaki, Hiroaki
    Kobayashi, Kazufumi
    Kiyono, Soichiro
    Nakamura, Masato
    Kanogawa, Naoya
    Saito, Tomoko
    Kondo, Takayuki
    Nakagawa, Ryo
    Nakamoto, Shingo
    Muroyama, Ryosuke
    Chiba, Tetsuhiro
    Hanaoka, Hideki
    Tsuji, Hiroshi
    Kato, Naoya
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [24] Clinical profile of hepatocellular carcinoma and neutrophil to lymphocyte ratio, platelet to lymphocyte ratio in hepatocellular carcinoma: cross sectional observational study
    Gayakwad, Rohan
    Chitra, S.
    Muthukumaran, K.
    Sathiya, G.
    Manimaran, M.
    Sumathi, K.
    Revathy, M. S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2019, 34 : 575 - 575
  • [25] Predictive Role of the Neutrophil-to-Lymphocyte Ratio in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib
    Tanoglu, Alpaslan
    Karagoz, Ergenekon
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (02) : 1063 - 1063
  • [26] The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
    Wang, Jing-Houng
    Chen, Yen-Yang
    Kee, Kwong-Ming
    Wang, Chih-Chi
    Tsai, Ming-Chao
    Kuo, Yuan-Hung
    Hung, Chao-Hung
    Li, Wei-Feng
    Lai, Hsiang-Lan
    Chen, Yen-Hao
    CANCERS, 2022, 14 (02)
  • [27] Preoperative Neutrophil-to-Lymphocyte Ratio Plus Platelet-to-Lymphocyte Ratio Predicts the Outcomes after Curative Resection for Hepatocellular Carcinoma
    Kabir, T.
    Ye, M.
    Noor, N. A. Mohd
    Woon, W.
    Junnarkar, S. P.
    Shelat, V. G.
    INTERNATIONAL JOURNAL OF HEPATOLOGY, 2019, 2019
  • [28] Neutrophil to lymphocyte ratio as an indicator of the malignant behaviour of hepatocellular carcinoma
    Okamura, Y.
    Sugiura, T.
    Ito, T.
    Yamamoto, Y.
    Ashida, R.
    Mori, K.
    Uesaka, K.
    BRITISH JOURNAL OF SURGERY, 2016, 103 (07) : 891 - 898
  • [29] Higher Absolute Lymphocyte Counts and Lower Des-γ-Carboxyprothrombin Levels After Treatment Initiation Are Associated With the Clinical Efficacy of Tremelimumab Plus Durvalumab Combination Therapy for Hepatocellular Carcinoma
    Inoue, Yuta
    Yano, Yoshihiko
    Kushida, Saeko
    Hirohata, Seiya
    Yoon, Seitetsu
    Yasutomi, Eiichiro
    Hirano, Hirotaka
    Kim, Soo Ki
    Yoshida, Ryutaro
    Ueda, Yoshihide
    Momose, Kenji
    Hayashi, Hiroki
    Kado, Takuo
    Nishi, Katsuhisa
    Tanaka, Hidenori
    Matono, Tomomitsu
    Yamamoto, Atsushi
    Tei, Hiroshi
    Nishioka, Chiharu
    Yagi, Yosuke
    Tamura, Shoji
    Sakane, Tatsuya
    Ehara, Mayumi
    Kawano, Miki
    Kitadai, Jun
    Matsuura, Takanori
    Shiomi, Yuuki
    Komatsu, Shohei
    Fukumoto, Takumi
    Tada, Toshifumi
    Kodama, Yuzo
    JGH OPEN, 2025, 9 (02):
  • [30] High Neutrophil–Lymphocyte Ratio and Delta Neutrophil–Lymphocyte Ratio Are Associated with Increased Mortality in Patients with Hepatocellular Cancer
    Nicole E. Rich
    Aarthi Parvathaneni
    Ahana Sen
    Mobolaji Odewole
    Ana Arroyo
    Arjmand R. Mufti
    Thomas A. Kerr
    Lafaine Grant
    Shannan R. Tujios
    Marlyn J. Mayo
    William M. Lee
    Ju Dong Yang
    Takeshi Yokoo
    Purva Gopal
    Yujin Hoshida
    Hao Zhu
    Adam C. Yopp
    Jorge A. Marrero
    Amit G. Singal
    Digestive Diseases and Sciences, 2022, 67 : 2666 - 2676
12345